SCHEMBL3678883

SCHEMBL3678883

NC(=O)CCCCCC(O)C(=O)Nc1ccccc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC2 Q92769 13/20 0.74
KMT2A Q03164 2/20 0.48
HDAC8 Q9BY41 14/20 0.48
HDAC6 Q9UBN7 12/20 0.48
HDAC3 O15379 11/20 0.48
HDAC1 Q13547 11/20 0.48
HDAC4 P56524 9/20 0.48
HDAC7 Q8WUI4 9/20 0.48
HDAC11 Q96DB2 9/20 0.48
HDAC9 Q9UKV0 9/20 0.48
HDAC5 Q9UQL6 9/20 0.48
HDAC10 Q969S8 8/20 0.48
KDM4E B2RXH2 1/20 0.46
BRD4 O60885 1/20 0.46
NCOR1 O75376 1/20 0.46
NR1I2 O75469 1/20 0.46
EGFR P00533 1/20 0.46
CYP3A4 P08684 1/20 0.46
LTA4H P09960 1/20 0.46
NR0B1 P51843 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7102450 0.89 HDAC2 (0.58) HDAC2KMT2ALTA4HMEN1POLB
SCHEMBL8144564 0.85 HDAC2 (1.00) HDAC2HDAC8HDAC6HDAC3HDAC1
SCHEMBL8152490 0.85 HDAC2 (1.00) HDAC2HDAC8HDAC6HDAC3HDAC1
SCHEMBL3586401 0.84 HDAC2 (0.69) HDAC2HDAC8HDAC6HDAC3HDAC1
SCHEMBL3585137 0.84 HDAC2 (0.69) HDAC2HDAC8HDAC6HDAC3HDAC1
SCHEMBL3581645 0.84 HDAC2 (0.69) HDAC2HDAC8HDAC6HDAC3HDAC1
SCHEMBL3591236 0.84 HDAC2 (0.69) HDAC2HDAC8HDAC6HDAC3HDAC1
SCHEMBL3242251 0.84 HDAC2 (0.97) HDAC2HDAC8HDAC6HDAC3HDAC1
SCHEMBL13369426 0.83 HDAC2 (0.68) HDAC2KMT2AHDAC8HDAC6HDAC3
SCHEMBL7563463 0.83 HDAC2 (0.68) HDAC2KMT2AHDAC8HDAC6HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4731199-A2 COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING COLORECTAL CANCER Burzynski, Stanislaw R. (US) 2026-04-29 EP disclosed
WO-2024263813-A2 COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING COLORECTAL CANCER BURZYNSKI STANISLAW R (US) 2024-12-26 WO disclosed
CN-106061481-B The combination of androgen receptor inhibitor and AKT inhibitor for treating cancer 诺华股份有限公司 2019-08-16 CN disclosed
CN-109806266-A Combination and its application use for cancer treatment 诺华股份有限公司 2019-05-28 CN disclosed
CN-109674801-A Combination 诺华股份有限公司 2019-04-26 CN disclosed
CN-109563043-A SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 葛兰素史密斯克莱知识产权发展有限公司 2019-04-02 CN disclosed
CN-106456642-A Combination comprising a btk inhibitor and an akt inhibitor 诺华股份有限公司 2017-02-22 CN disclosed
WO-2015184260-A2 METHODS FOR TREATING MENDELIAN DISORDERS OF THE EPIGENETIC MACHINERY THE JOHNS HOPKINS UNIVERSITY (US) 2015-12-03 WO disclosed
CN-101909630-A Methods and compounds for preventing and treating a tumour AGENCY SCIENCE TECH & RES 2010-12-08 CN disclosed
EP-2167090-A2 HDAC INHIBITORS AND HORMONE TARGETED DRUGS FOR THE TREATMENT OF CANCER University of Maryland, Baltimore (US) 2010-03-31 EP disclosed
WO-2009126662-A1 ADMINISTRATION OF AN INHIBITOR OF HDAC, AN INHIBITOR OF HER-2, AND A SELECTIVE ESTROGEN RECEPTOR MODULATOR SYNDAX PHARMACEUTICALS, INC. (US) 2009-10-15 WO disclosed
WO-2009064300-A1 COMBINATIONS OF HDAC INHIBITORS AND CYTOKINES/GROWTH FACTORS THE JOHNS HOPKINS UNIVERSITY (US) 2009-05-22 WO disclosed
WO-2008154402-A2 HDAC INHIBITORS AND HORMONE TARGETED DRUGS FOR THE TREATMENT OF CANCER UNIVERSITY OF MARYLAND, BALTIMORE (US) 2008-12-18 WO disclosed